Covidien (COV) and Nuvo Research Announce the U.S. FDA Approved New Drug Application for Pennsaid
More News related to COV
- Covidien (COV) Announces FDA Extends Review of NDA for Exalgo
- FDA Extends Review of NDA for Exalgo(TM)
- Morgan Keegan Starts BDX, HAE, BCR, MASI, COO at Outperform, BAX, HRC, COV, TFX, ISRG at Market Perform
- Covidien (COV) Posts Q4 adj.-EPS of $0.72, Tops by 4c
- Covidien Reports Fourth-Quarter and Fiscal 2009 Results
More News related to Corporate News
- FortuNet (FNET) To Tender Outstanding Shares at $1.70/Share to Yuri Itkis Trust
- Citi (C) Sells Diners Club to Bank of Montreal (BMO) for Approx. $1B
- Icahn Outbids Penn National Gaming (PENN) On Bankrupt Fontainebleau Casino Project
- Overstock.com (OSTK) Dismisses Grant Thorton as Public Accounting Firm
- First Regional Bancorp (FRGB) Announces Adjustment in Taxes and Loan Losses
Covidien (NYSE: COV), a leading global provider of healthcare products, and Nuvo Research Inc. (TSX: NRI), a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid Topical Solution (diclofenac sodium topical solution) 1.5% w/w.
Pennsaid Topical Solution is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of the signs and symptoms of osteoarthritis of the knee.
Nuvo develops drug products delivered to and through the skin using its topical and transdermal drug delivery technologies. Covidien is the largest supplier of controlled pain medications in the United States based on number of prescriptions.
In June, the companies announced that Mallinckrodt Inc., a Covidien company, had entered into a license and development agreement with Nuvo that encompasses Pennsaid Topical Solution and its follow-on topical diclofenac formulation, Pennsaid Plus Gel, which is currently under development. Under the agreement, Covidien is responsible for all U.S. commercialization activities, including marketing, selling and medical education and is responsible for the clinical development of Pennsaid Plus. Nuvo owns and maintains the intellectual property rights to the products and also will be responsible for manufacturing.
As a result of the FDA approval of Pennsaid Topical Solution, Nuvo will receive a $15 million milestone payment from Covidien. Going forward, Nuvo will receive royalties on net U.S. sales of Pennsaid at rates that are consistent with industry standards. Nuvo will also be eligible to receive additional escalating sales milestone payments for Pennsaid and Pennsaid Plus totaling up to US$100 million.
The launch of Pennsaid Topical Solution, which Covidien anticipates in the first half of calendar 2010, will include a NSAID medication guide for prescribers, pharmacists and patients.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
